Emad Siddiqui
About
In The Last Decade
Emad Siddiqui
71 papers receiving 2.5k citations
Peers
Comparison fields: 5 of 95
- Urology 1.8k
- Rheumatology 1.5k
- Epidemiology 1.1k
- Endocrinology, Diabetes and Metabolism 466
- Surgery 310
Countries citing papers authored by Emad Siddiqui
This map shows the geographic impact of Emad Siddiqui's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Emad Siddiqui with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Emad Siddiqui more than expected).
Fields of papers citing papers by Emad Siddiqui
This network shows the impact of papers produced by Emad Siddiqui. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Emad Siddiqui. The network helps show where Emad Siddiqui may publish in the future.
Co-authorship network of co-authors of Emad Siddiqui
This figure shows the co-authorship network connecting the top 25 collaborators of Emad Siddiqui. A scholar is included among the top collaborators of Emad Siddiqui based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Emad Siddiqui. Emad Siddiqui is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 8 | |
| 2 | 4 | |
| 3 | 3 | |
| 4 | 4 | |
| 5 | 45 | |
| 6 | 8 | |
| 7 | 18 | |
| 8 | 9 | |
| 9 | 147 | |
| 10 | 6 | |
| 11 | 13 | |
| 12 | 195 | |
| 13 | Age-related efficacy of the selective ß3-adrenoceptor agonist mirabegron for the treatment of overactive bladder (OAB): pooled analysis of three prospective, randomised Phase III studies in patients aged >= 65 years | 8 |
| 14 | The Potent and Selective Beta3-adrenoceptor Agonist Mirabegron Improves Patient-reported Outcomes in Overactive Bladder–Results from Two Phase III Studies | 1 |
| 15 | Efficacy of mirabegron in patients with overactive bladder (OAB): Pre-specified analysis of three randomised, double-blind, placebo-controlled, Phase III studies | 4 |
| 16 | PERSISTENCE PATTERNS WITH ORAL ANTIMUSCARINICS USED FOR THE TREATMENT OF OVERACTIVE BLADDER IN UK GENERAL PRACTICE: A RETROSPECTIVE ANALYSIS BY AGE | 1 |
| 17 | 1 | |
| 18 | 1 | |
| 19 | 12 | |
| 20 | Malignant Melanoma Of The Female Urethra | 1 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.